One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Bipolar Disorder Market

[ 英語タイトル ] Bipolar Disorder Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0083370
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - AbbVie Inc.
- Allergan PLC
- AstraZeneca Plc
- Eli Lilly and Company
- GlaxoSmithKline Plc
- Janssen Pharmaceuticals Inc.
- Novartis AG
- Otsuka Holdings Co. Ltd
- Pfizer Inc.

[Report Description]

The bipolar disorder market is expected to register a CAGR of nearly 2.5% during the forecast period. The major factors for the growth of. the bipolar disorder market includes the increasing prevalence of the bipolar disorder, rising initiatives by government institutes to increase the awareness, and technological advancements. There is an increasing prevalence of bipolar disorder owing to the various risk factors, such as high stress, substance abuse, and others. According to the estimates of the Institute for Health Metrics and Evaluation (IHME), Global Burden of Diseases, the prevalence of bipolar disorder across the world varies from 0.3 to 1.2% by country. In 2017 around 46 million people in the world had bipolar disorder, with 52% and 48% being female and male, respectively. The typical age of onset is the late teens or the early 20s, and a history of depression is common in people diagnosed with bipolar. The probability of men and women are being affected by bipolar disorder is similar. Hence, the rise in the cases of the disease and the increasing need to manage them effectively has led to the growth of the bipolar disorder market.

Key Market Trends

Antipsychotic Drugs are Expected to be Fastest Growing Segment Over the Forecast Period

Antipsychotic medications are used as a short-term treatment for bipolar disorder to control psychotic symptoms, such as hallucinations, delusions, or mania symptoms. These symptoms may occur during acute mania or severe depression. Some also treat bipolar depression, and several have demonstrated long-term value in preventing future episodes of mania or depression. In people with bipolar disorder, antipsychotics are also used "off label" as sedatives, for insomnia, for anxiety, and/or for agitation. Often, they are taken with a mood-stabilizing drug and can decrease the symptoms of mania until mood stabilizers take full effect. Some antipsychotics seem to help stabilize moods on their own. As a result, they may be used alone as a long-term treatment for people who do not tolerate or respond to lithium and anticonvulsants. A few antipsychotic drugs include aripiprazole (Abilify), asenapine (Saphris), cariprazine (Vraylar), clozapine (Clozaril), lurasidone (Latuda), olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal), and ziprasidone (Geodon).

North America is Expected to Dominate the Market Over the Forecast Period

North America is found to hold a major share for the bipolar disorder market and is expected to show a similar trend over the forecast period, without significant fluctuations. Due to the increasing cases of bipolar disorder and the presence of better healthcare infrastructure, the market is expected to witness high growth over the forecast period. According to the data published by the National Alliance on Mental Illness, around 1 in 5 adults in the United States experiences mental illness in a given year. Hospitalization is required for severe episodes of mania and depression to protect the patients from injuring themselves or others. According to the NIMH, bipolar I disorder is characterized in part by manic symptoms that are so severe that the person needs immediate hospital care. There is a huge need to tackle bipolar disorder, as it is an increasing problem, and hence, the market for bipolar disorder is expected to grow during the forecast period.

Competitive Landscape

The market studied is a moderately consolidated market owing to the presence of small and large market players. Some of the market players are AbbVie Inc., Allergan PLC, AstraZeneca Plc, Eli Lilly and Company, GlaxoSmithKline Plc, Janssen Pharmaceuticals Inc., Novartis AG, Otsuka Holdings Co. Ltd, and Pfizer Inc.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Bipolar Disorder
4.2.2 Rising initiative by Government Institutes to Increase the Awareness
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 Side Effects Associated with Bipolar Drugs
4.3.2 Misdiagnosis of Bipolar Disorder
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Drug Class
5.1.1 Mood stabilizer
5.1.2 Anticonvulsant
5.1.3 Antipsychotic Drug
5.1.4 Antidepressant Drug
5.1.5 Other Classes of Drug
5.2 By Mechanism of Action
5.2.1 Selective Serotonin Reuptake Inhibitor
5.2.2 Serotonin Norepinephrine Reuptake Inhibitor
5.2.3 Tricyclic Antidepressant Drug
5.2.4 Beta Blockers
5.2.5 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia - Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Allergan PLC
6.1.3 AstraZeneca Plc
6.1.4 Eli Lilly and Company
6.1.5 GlaxoSmithKline Plc
6.1.6 Janssen Pharmaceuticals Inc.
6.1.7 Novartis AG
6.1.8 Otsuka Holdings Co. Ltd
6.1.9 Pfizer Inc.




Recommended reports